摘要
Background: PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02 in combination with 5-FU and LV, in patients with advanced refractory solid tumors. Methods: Patients were enrolled in cohorts to receive PEP02 from 60 to 120 mg/m2 (dose expressed as the irinotecan hydrochloride trihydrate salt) as a 90-min intravenous infusion on day 1, followed by 24 h infusion of 5-FU 2,000 mg/m2 and LV 200 mg/m2 on days 1 and 8, every 3 weeks. Results: A total of 16 patients were assigned to four dose levels, 60 (three patients), 80 (six patients), 100 (five patients) and 120 mg/m2 (two patients). DLT was observed in four patients, two at the 100 mg/m2 dose level (one had grade III infection with hypotension and grade III hemorrhage; the other had grade III diarrhea and grade IV neutropenia), and two at the 120 mg/m2 dose level (one had grade III diarrhea and grade IV neutropenia; the other had grade III diarrhea). The MTD of PEP02 was determined as 80 mg/m2. The most common treatment-related adverse events were nausea (81%), diarrhea (75%) and vomiting (69%). Among the six patients who received the MTD, one patient exhibited partial response, four patients had stable disease and one showed progressive disease. Pharmacokinetic data showed that PEP02 had a lower peak plasma concentration, longer half-life, and increased area under the plasma concentration-time curve from zero to time t of SN-38 than irinotecan at similar dose level. Conclusions: The MTD of PEP02 on day 1 in combination with 24-h infusion of 5-FU and LV on days 1 and 8, every 3 weeks was 80 mg/m2, which will be the recommended dose for future studies. Trial registration: The trial was retrospectively registered (NCT02884128) with date of registration: August 12, 2016.
原文 | 英語 |
---|---|
文章編號 | 907 |
期刊 | BMC Cancer |
卷 | 16 |
發行號 | 1 |
DOIs | |
出版狀態 | 已發佈 - 11月 21 2016 |
ASJC Scopus subject areas
- 腫瘤科
- 遺傳學
- 癌症研究
指紋
深入研究「A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors」主題。共同形成了獨特的指紋。資料集
-
Additional file 1: Table S1. of A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
Wang, C. (Creator), Chen, L. (Contributor), Chiang, N. (Contributor), Yeh, C. G. (Contributor), Hsieh, R. (Contributor), Chao, T. (Contributor) & Wang, Y. (Creator), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3646481_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3646481_d1.v1
資料集: Dataset
-
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
Chiang, N. (Contributor), Chao, T. (Contributor), Hsieh, R. (Contributor), Wang, C. (Creator), Wang, Y. (Creator), Yeh, C. G. (Contributor) & Chen, L. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3646481.v1, https://doi.org/10.6084%2Fm9.figshare.c.3646481.v1
資料集: Dataset